These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 15671091)
41. Growth hormone (GH)-releasing hormone tonically inhibits in vitro endogenous somatostatin in human GH-secreting tumors. Mouhieddine OE; Levy L; Benlot C; Peillon F; Joubert D J Clin Endocrinol Metab; 1995 May; 80(5):1691-5. PubMed ID: 7745020 [TBL] [Abstract][Full Text] [Related]
42. An unusual cause of acromegaly. Lock KY; Lau IT; Yeung CK; Chan CP Hong Kong Med J; 2014 Aug; 20(4):331-4. PubMed ID: 25104005 [TBL] [Abstract][Full Text] [Related]
43. Comment of long-acting lanreotide inducing clinical and biochemical remission of acromegaly caused by disseminated GHRH secreting carcinoid. Krassowski J; Zgliczyński W; Jeske W; Zgliczyński S J Clin Endocrinol Metab; 1999 May; 84(5):1761-2. PubMed ID: 10323416 [No Abstract] [Full Text] [Related]
44. Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas. Rubinfeld H; Hadani M; Barkai G; Taylor JE; Culler MD; Shimon I J Clin Endocrinol Metab; 2006 Jun; 91(6):2257-63. PubMed ID: 16595604 [TBL] [Abstract][Full Text] [Related]
45. Interleukin-1 beta modulates the acute release of growth hormone-releasing hormone and somatostatin from rat hypothalamus in vitro, whereas tumor necrosis factor and interleukin-6 have no effect. Honegger J; Spagnoli A; D'Urso R; Navarra P; Tsagarakis S; Besser GM; Grossman AB Endocrinology; 1991 Sep; 129(3):1275-82. PubMed ID: 1678697 [TBL] [Abstract][Full Text] [Related]
46. Acromegaly induced by ectopic secretion of GHRH: a review 30 years after GHRH discovery. Borson-Chazot F; Garby L; Raverot G; Claustrat F; Raverot V; Sassolas G; Ann Endocrinol (Paris); 2012 Dec; 73(6):497-502. PubMed ID: 23122576 [TBL] [Abstract][Full Text] [Related]
47. Comparison of the sensitivity of growth hormone secretion to somatostatin in vivo and in vitro in acromegaly. Kelijman M; Williams TC; Downs TR; Frohman LA J Clin Endocrinol Metab; 1988 Nov; 67(5):958-63. PubMed ID: 2903171 [TBL] [Abstract][Full Text] [Related]
48. Somatostatin and growth hormone-releasing hormone in normal and tumoral human breast tissue: endogenous content, in vitro pulsatile release, and regulation. Benlot C; Lévy L; Fontanaud P; Roche A; Rouannet P; Joubert D J Clin Endocrinol Metab; 1997 Feb; 82(2):690-6. PubMed ID: 9024278 [TBL] [Abstract][Full Text] [Related]
49. Acromegaly caused by a growth hormone-releasing hormone secreting carcinoid tumour of the lung: the effect of octreotide treatment. de Jager CM; de Heide LJ; van den Berg G; Wolthuis A; van Schelven WD Neth J Med; 2007; 65(7):263-6. PubMed ID: 17656813 [TBL] [Abstract][Full Text] [Related]
50. Role of growth hormone (GH)-releasing hormone and somatostatin in the mediation of clonidine-induced GH release in sheep. Magnan E; Cataldi M; Guillaume V; Mazzocchi L; Dutour A; Razafindraibe H; Sauze N; Renard M; Oliver C Endocrinology; 1994 Feb; 134(2):562-7. PubMed ID: 7905408 [TBL] [Abstract][Full Text] [Related]
51. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. Ain KB; Taylor KD; Tofiq S; Venkataraman G J Clin Endocrinol Metab; 1997 Jun; 82(6):1857-62. PubMed ID: 9177396 [TBL] [Abstract][Full Text] [Related]
52. Suppression of growth hormone (GH) hypersecretion due to ectopic GH-releasing hormone (GHRH) by a selective GHRH antagonist. Jaffe CA; DeMott-Friberg R; Frohman LA; Barkan AL J Clin Endocrinol Metab; 1997 Feb; 82(2):634-7. PubMed ID: 9024267 [TBL] [Abstract][Full Text] [Related]
53. Acromegaly secondary to an incidentally discovered growth-hormone-releasing hormone secreting bronchial carcinoid tumour associated to a pituitary incidentaloma. Verrua E; Ronchi CL; Ferrante E; Ferrari DI; Bergamaschi S; Ferrero S; Zatelli MC; Branca V; Spada A; Beck-Peccoz P; Lania AG Pituitary; 2010 Sep; 13(3):289-92. PubMed ID: 18946740 [TBL] [Abstract][Full Text] [Related]
54. Severity of the catabolic condition differentially modulates hypothalamic expression of growth hormone-releasing hormone in the fasted mouse: potential role of neuropeptide Y and corticotropin-releasing hormone. Luque RM; Park S; Kineman RD Endocrinology; 2007 Jan; 148(1):300-9. PubMed ID: 17038558 [TBL] [Abstract][Full Text] [Related]
55. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. Zatelli MC; Tagliati F; Taylor JE; Rossi R; Culler MD; degli Uberti EC J Clin Endocrinol Metab; 2001 May; 86(5):2161-9. PubMed ID: 11344221 [TBL] [Abstract][Full Text] [Related]
56. The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells. Zitzmann K; Andersen S; Vlotides G; Spöttl G; Zhang S; Datta R; Culler M; Göke B; Auernhammer CJ Neuroendocrinology; 2013; 98(2):128-36. PubMed ID: 23797089 [TBL] [Abstract][Full Text] [Related]
57. Somatostatin Receptor Expression Is Associated With Metastasis and Patient Outcome in Pulmonary Carcinoid Tumors. Vesterinen T; Leijon H; Mustonen H; Remes S; Knuuttila A; Salmenkivi K; Vainio P; Arola J; Haglund C J Clin Endocrinol Metab; 2019 Jun; 104(6):2083-2093. PubMed ID: 30657933 [TBL] [Abstract][Full Text] [Related]
58. A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Janson ET; Gobl A; Kälkner KM; Oberg K Cancer Res; 1996 Jun; 56(11):2561-5. PubMed ID: 8653698 [TBL] [Abstract][Full Text] [Related]
59. Growth-hormone releasing hormone in a bronchial carcinoid. Huber RM; Schopohl J; Losa M; Wolfram G; Thetter O; Permanetter W; v Werder K Cancer; 1991 May; 67(10):2538-42. PubMed ID: 2015554 [TBL] [Abstract][Full Text] [Related]
60. Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role. Kanakis G; Grimelius L; Spathis A; Tringidou R; Rassidakis GZ; Öberg K; Kaltsas G; Tsolakis AV Neuroendocrinology; 2015; 101(3):211-22. PubMed ID: 25765100 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]